Patient selection for antibody therapy

In the future, the optimal treatment may be determined by clinical and biological characteristics of individual patients. Patient characteristics that appear to predict those patients more likely to respond to rituximab therapy include polymorphisms for FcRgammalll, which represents the binding site on natural killer cells for the rituximab antibody,68 and DNA microarray signatures.69 Moreover, in large B-cell NHL the benefit of rituximab appears to be limited to patients whose tumors overexpress the bcl-2 gene.70 Whether these observations will determine which patients will receive rituximab remains to be seen.

0 0

Post a comment